Journal Watch · Nature Communications · 2026

The benchmarking and application of tag-degraders in vivo to validate therapeutic targets.

Together, this resource will assist researchers in choosing the right degrader and tag for their own applications.

Magtoto CM, Mieruszynski S, Dong H et al.Nature Communications3 min readPharma relevance 60/100

DOI: 10.1038/s41467-026-73681-1PMID: 42215500Study type: preclinical (animal / model) study

TL;DR

Together, this resource will assist researchers in choosing the right degrader and tag for their own applications.

Key findings

  • Using an FKBP<sup>F36V</sup> knock-in mouse expressing 65K-FKBP<sup>F36V</sup>, we reveal target specific degradation kinetics, and a critical requirement for 65K in mice.
  • Together, this resource will assist researchers in choosing the right degrader and tag for their own applications.

What they did

However, each degrader has a distinct pharmacokinetic profile that will influence its effectiveness across tissues. To create a resource to enable the most appropriate choice of tag-degrader, we benchmark the dTAG, HaloPROTAC, and NanoTAC systems in vivo by employing a transgenic mouse expressing a reporter protein targetable by these tag-degraders. Through various treatment regimes, we characterise each degrader profile across a panel of 20 tissues and organs, highlighting the superior degradation by dTAG molecules, and identify differences between degradation in whole tissues versus single cell populations.

Full abstract (original)

Background: Transitioning a candidate therapeutic target from bench to bedside requires significant time and financial investment, yet clinical success remains low often due to poor on-target toxicity assessment during preclinical validation. Tag-degraders provide a tool to improve target validation by enabling degradation of any protein of interest via a degron-tag. This drug-based, reversible, and dose-dependent method of protein removal can mimic degrader-based drug treatments and assess the implications of target protein depletion in vivo.

What they did: However, each degrader has a distinct pharmacokinetic profile that will influence its effectiveness across tissues. To create a resource to enable the most appropriate choice of tag-degrader, we benchmark the dTAG, HaloPROTAC, and NanoTAC systems in vivo by employing a transgenic mouse expressing a reporter protein targetable by these tag-degraders. Through various treatment regimes, we characterise each degrader profile across a panel of 20 tissues and organs, highlighting the superior degradation by dTAG molecules, and identify differences between degradation in whole tissues versus single cell populations.

Results & conclusions: Using an FKBP<sup>F36V</sup> knock-in mouse expressing 65K-FKBP<sup>F36V</sup>, we reveal target specific degradation kinetics, and a critical requirement for 65K in mice. Together, this resource will assist researchers in choosing the right degrader and tag for their own applications.

Abstract © the authors / Nature Communications (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1038/s41467-026-73681-1 · PubMed 42215500.

Why it matters for pharma & biotech

  • Directly relevant to teams in small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: small-molecule drug discovery

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Nature Communications study find?

Together, this resource will assist researchers in choosing the right degrader and tag for their own applications.

What type of study is this?

It is a preclinical (animal / model) study, published in Nature Communications in 2026. However, each degrader has a distinct pharmacokinetic profile that will influence its effectiveness across tissues.

Where can I read the original paper?

The original is at the publisher via DOI 10.1038/s41467-026-73681-1. PubMed ID: 42215500. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Magtoto CM, Mieruszynski S, Dong H et al.. The benchmarking and application of tag-degraders in vivo to validate therapeutic targets.. Nature Communications (2026). DOI: 10.1038/s41467-026-73681-1.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/the-benchmarking-and-application-of-tag-degraders-in-vivo-to-validate-th-736811/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides